CHMP recommends pediatric label expansion for Merck's Cubicin

EMA's CHMP recommended approval of a label expansion for Cubicin daptomycin (MK-3009) from Merck & Co. Inc. (NYSE:MRK) to include patients ages 1-17 with Staphylococcus aureus bacteremia associated with complicated skin or soft-tissue infections (cSSTI). The cyclic lipopeptide antibiotic is already approved in the EU to treat adults with S. aureus bacteremia associated with cSSTI or right-sided infective endocarditis...